FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a …
FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder Read More